The company is a pioneer in LNP delivery of nucleic acids, using its proprietary LNP platform to study more than a dozen discrete product candidates. It has been used to develop the first and only approved systemic RNA-LNP product (patisiran), which enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing.